These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
233 related items for PubMed ID: 23532816
21. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure. Demir M, Kaya H, Taylan M, Ekinci A, Yılmaz S, Teke F, Sezgi C, Tanrikulu AC, Meteroglu F, Senyigit A. Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653 [Abstract] [Full Text] [Related]
22. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Burt BM, Lee HS, Lenge De Rosen V, Hamaji M, Groth SS, Wheeler TM, Sugarbaker DJ. Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420 [Abstract] [Full Text] [Related]
23. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF. Med Clin (Barc); 2009 Oct 03; 133(12):449-53. PubMed ID: 19783262 [Abstract] [Full Text] [Related]
25. Diagnostic performance of CTLA-4, carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion. Chen M, Xie S, Wan C, Zeng N, Wu Y, Qin J, Shen Y, Wen F. Postgrad Med; 2017 Aug 03; 129(6):644-648. PubMed ID: 28506100 [Abstract] [Full Text] [Related]
31. Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1. Son SM, Han HS, An JY, Choe KH, Lee KM, Lee KH, Kim SS, Lee YM, Lee HC, Song HG, Lee OJ. Pathology; 2015 Feb 03; 47(2):123-9. PubMed ID: 25551300 [Abstract] [Full Text] [Related]
34. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. Schneider MA, Muley T, Kahn NC, Warth A, Thomas M, Herth FJ, Dienemann H, Meister M. Oncotarget; 2016 Nov 01; 7(44):71285-71297. PubMed ID: 27713145 [Abstract] [Full Text] [Related]
35. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW. Thorax; 2014 Oct 01; 69(10):895-902. PubMed ID: 25037982 [Abstract] [Full Text] [Related]
38. Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report. Canessa PA, Ferro P, Manta C, Sivori M, Franceschini MC, Fedeli F, Roncella S. Med Oncol; 2013 Oct 01; 30(3):649. PubMed ID: 23873013 [Abstract] [Full Text] [Related]
39. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology. Cappellesso R, Galasso M, Nicolè L, Dabrilli P, Volinia S, Fassina A. Cancer Cytopathol; 2017 Aug 01; 125(8):635-643. PubMed ID: 28449331 [Abstract] [Full Text] [Related]
40. MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions. Birnie KA, Prêle CM, Musk AWB, de Klerk N, Lee YCG, Fitzgerald D, Allcock RJN, Thompson PJ, Creaney J, Badrian B, Mutsaers SE. Dis Markers; 2019 Aug 01; 2019():8628612. PubMed ID: 31481984 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]